VIVUS — Technical Presentation (November 2009)
29 slides from VIVUS's technical presentation, Nov 18, 2009
Slide 1: Avanafil REVIVE (TA-301) Results
Avanafil REVIVE (TA-301) Results November 18, 2009
Slide 2: Today's Speakers
Today’s Speakers Leland F. Wilson, Chief Executive Officer Dr. Charles H. Bowden, Senior Director Clinical Development Dr. Wesley W. Day, Vice President Clinical Development Dr. Leroy Jones, Clinical Associate Professor, Urology, University of Texas Health Science Center, San Antonio
Slide 3: Forward-looking statements
VIVUS cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests,“ "assuming," "designed" and similar exp
Slide 4: REVIVE (TA-301): Summary
4 Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com REVIVE (TA-301): Summary • All primary FDA endpoints achieved for all 3 doses • Largest of three pivotal phase 3 studies • Conducted under Special Protocol Assessment (SPA) • Outstanding results from REVIVE • 77% of attempts among pa
Slide 5: Avanafil: Why another PDE5i?
Avanafil: Why another PDE5i? Current sales of PDE5i’s exceed $3.8 billion worldwide Sildenafil $1.9 billion Tadalafil $1.4 billion Vardenafil $0.5 billion Total prescriptions and revenues continue to grow New prescriptions growing at 3.3% per year Revenue increasing at a rate of 11.3% per year Avera
Slide 6: Avanafil: Background
Avanafil: Background Licensed worldwide (except certain Asian countries) rights from Mitsubishi Tanabe Pharma Corporation Patent protected through 2020 (US 6,656,935) Highly specific for PDE5 Fast to Tmax Potential to be positioned as true on-demand therapy with excellent safety and tolerability
Slide 7: Avanafil Pharmacokinetics Profile Supports True On-demand Use
Avanafil Pharmacokinetics Profile Supports True On-demand Use 120 Tadalafil (Cialis®) 60 Vardenafil (Levitra®) 60 Sildenafil (Viagra®) ~35 Avanafil Tmax (min)
Slide 8: Avanafil: Greater Selectivity for PDE5 Supports Greater Safety and Tolerability
Avanafil: Greater Selectivity for PDE5 Supports Greater Safety and Tolerability Pituitary,Testes Retina Penis Heart, Brain Target Tissues 25 550 1 10,500 Tadalafil >19,230 121 1 10,192 Avanafil 1 1 PDE5 1,012 375 PDE1 Compound PDE6 PDE11A Sildenafil 16 4,875 Vardenafil 21 5,952 Data on file, Mitsubi
Slide 9: PDE5i Market: Expanding Market
PDE5i Market: Expanding Market Differentiated profile for Cialis shows new entrants can succeed US PDE5i Retail Market Annualized Unit Volume (MM Tablets) (3-Months Jun - Aug Actuals Annualized For Each Year) 0 20 40 60 80 100 120 140 160 2003 2004 2005 2006 2007 2008 2009 Units In Millions Of Table
Slide 10: Market Need for New PDE5 Therapy
Market Need for New PDE5 Therapy Large and growing market Patients less than satisfied, lots of switching New entrants with differentiated position able to take market share Patients looking for on-demand therapy with lower frequency of side effects
Slide 11: REVIVE (TA-301): Phase Results
REVIVE (TA-301): Phase 3 Results Charles H. Bowden, M.D.
Slide 12: REVIVE (TA-301): Study Design
REVIVE (TA-301): Study Design Randomized N=646 Treatment (12 weeks) Avanafil 100 mg (n=161) Avanafil 50 mg (n=161) Placebo (n=162) 4 week Non-treatment Run-in period Avanafil 200 mg (n=162)
Slide 13: REVIVE (TA-301): Real World Use
REVIVE (TA-301): Real World Use No restrictions on food No restrictions on alcohol Use of alpha blockers allowed Prior use of PDE5 therapies not excluded 72% of patients had previously used ED treatment
Slide 14: REVIVE: Baseline Demographics
REVIVE: Baseline Demographics Baseline 467 155 Patients (Intent-to-treat) Avanafil Placebo 12.4 75.9 23-77 56 Average Age 56 Age Range 23-88 Duration of ED (months) 79.3 Erectile function (IIEF) 12.7
Slide 15: REVIVE: Avanafil Treatment Leads to Successful Vaginal Penetration (SEP2)
REVIVE: Avanafil Treatment Leads to Successful Vaginal Penetration (SEP2) *p<0.001 active vs. placebo change from baseline Nearly 8 out of 10 times the erection is sufficient for penetration at 200 mg of avanafil * * * 47% 45% 46% 48% 54% 64% 74% 77% 0% 20% 40% 60% 80% Placebo 50 mg 100 mg 200 mg Ba
Slide 16: REVIVE: Avanafil Treatment Leads to Successful Intercourse (SEP3)
REVIVE: Avanafil Treatment Leads to Successful Intercourse (SEP3) Nearly 6 out of 10 times avanafil patients had successful intercourse with 100 mg and 200 mg *p<0.001 active vs. placebo change from baseline * * * 13% 13% 14% 12% 27% 41% 57% 57% 0% 20% 40% 60% Placebo 50 mg 100 mg 200 mg Baseline En
Slide 17: REVIVE: Avanafil Treatment Significantly Improves Erectile Function
REVIVE: Avanafil Treatment Significantly Improves Erectile Function Mild 17-25 Moderate 11-16 ED Severity Severe < 10 IIEF-EF Domain Scores *p < 0.001 active vs. placebo change from baseline * * * 12.4 12.7 12.6 12.7 15.3 18.1 20.9 22.2 0 5 10 15 20 25 Placebo 50 mg 100 mg 200 mg Baseline End of Tre
Slide 18: REVIVE: High Number of Attempts in Minutes or Less
REVIVE: High Number of Attempts in 30 Minutes or Less 83% of all attempts 60 minutes or less Attempts n=11,614 4% of all attempts after 2 hours 4,360 3,202 2,031 1,515 506 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 < 30 30-45 45-60 60-120 >120 Minutes post dose Number of attempts
Slide 19: REVIVE: Avanafil Achieves Success in Minutes or Less
REVIVE: Avanafil Achieves Success in 30 Minutes or Less Successful Attempts (SEP3) in < 30 minutes 31% 53% 62% 58% 0% 20% 40% 60% Placebo 50 mg 100 mg 200 mg Placebo 50 mg 100 mg 200 mg
Slide 20: REVIVE: Success At Any Time
REVIVE: Success At Any Time Consistent Results at All Timepoints 0% 20% 40% 60% < 30 30-45 45-60 60-120 >120 Minutes Post Dose Percent Successful Attempts Placebo 50 mg 100 mg 200 mg
Slide 21: Avanafil: Lasting Efficacy Beyond Hours
Avanafil: Lasting Efficacy Beyond 6 Hours Percent Successful Attempts 25% 25% 61% 65% 62% 77% 76% 83% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% > 4 hours > 6 hours Placebo 50 mg 100 mg 200 mg
Slide 22: REVIVE: Low Discontinuation Rate and SAE's
REVIVE: Low Discontinuation Rate and SAE’s 0% 0% 0% 0% Drug related SAE’s 0% 0.6%* 0% 0% Deaths Percent of patients Placebo Avanafil 50 mg Avanafil 100 mg Avanafil 200 mg Discontinuation due to AEs 3.1% 1.9% 3.7% 2.5% Serious Adverse Events (SAE) 1.2% 0.6% 1.9% 1.9% * One subject, not related to dru
Slide 23: REVIVE: Treatment-Emergent Adverse Events >1%
REVIVE: Treatment-Emergent Adverse Events >1% 1.7% 0.6% Bronchitis Placebo (n=161) Avanafil (n=483) Headache 1.2% 7.0% Flushing 0.0% 4.6% Nasal Congestion 1.2% 2.3% Back Pain 0.6% 2.1% Nasopharyngitis 1.2% 1.7% Diarrhea 0.6% 1.2% Upper Respiratory Infection 0.6% 1.2% Sinus Infection 1.9% 0.6% Pain i
Slide 24: Commonly Reported Side Effects for PDE5 Therapies
Commonly Reported Side Effects for PDE5 Therapies* 3% 6% 10% 11% Levitra 8% 5% 0% Dyspepsia 2% 9% 12% Viagra Avanafil Cialis Headache 6% 8% Flushing 5% 2% Nasal Congestion 1% 2% *Placebo adjusted pooled for all doses from labels of approved PDE5 therapies for most common side effects reported. No he
Slide 25: Avanafil Development Program
Avanafil Development Program Wesley W. Day, PhD Vice President Clinical Development
Slide 26: Avanafil: Well-Designed Phase 3 Program
Late 2010 16 wks 375 Post-Radical Prostatectomy REVIVE-RP (TA-303) Q4 2009 16 wks 646 General REVIVE (TA-301) Mid 2010 16 wks 375 Diabetics REVIVE-D (TA-302) Late 2010 6 mos 1 year 300 100 Open label REVIVE-S (TA-314) Duration Studies Population Pts Data Expected Avanafil: Well-Designed Phase 3 Prog
Slide 27: Avanafil Development Program On Track
Avanafil Development Program On Track All nonclinical and clinical studies necessary to support NDA are completed, in progress or planned Clinical Pharmacology OB-140 TQT study completed - no findings of concern Nitrate study complete – avanafil less interaction than sildenafil Clinical Pharmacology
Slide 28: Dr. Leroy Jones
Dr. Leroy Jones Clinical Associate Professor, Urology, University of Texas Health Science Center, San Antonio
Slide 29: REVIVE (TA-301): Summary
30 Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com REVIVE (TA-301): Summary • All primary FDA endpoints achieved for all 3 doses • Largest of three pivotal phase 3 studies • Conducted under Special Protocol Assessment (SPA) • Outstanding results from REVIVE • 77% of attempts among p